Innokin Trine: A Revolutionary Rechargeable E-Cigarette with Replaceable Battery

Oct.12.2024
Innokin Trine: A Revolutionary Rechargeable E-Cigarette with Replaceable Battery
A new Innokin Trine e-cigarette with replaceable battery has hit shelves in Europe, meeting upcoming EU regulations.

Recently, 2Firsts noticed a new type of replaceable battery e-cigarette called the Innokin Trine being showcased at a tobacco exhibition in Dortmund. The product, launched by e-cigarette brand Innokin, is now available on e-cigarette retail websites in regions such as the UK and Germany. With its design allowing for replaceable batteries, the product complies with the new regulations set to be implemented by the EU Battery Directive in 2026.

Innokin Trine: A Revolutionary Rechargeable E-Cigarette with Replaceable Battery
Innokin Trine displayed at the tobacco exhibition in Dortmund by Innokin|Image source: 2Firsts


At the recent Dortmund tobacco exhibition, several exhibitors showcased e-cigarette products with replaceable batteries, including disposable, pod-based, and open-system devices, in response to the EU's Battery Directive. According to the directive, by 2026, batteries in portable devices (such as disposable e-cigarettes) must be easily removable and replaceable by the user.

Innokin Trine: A Revolutionary Rechargeable E-Cigarette with Replaceable Battery
Image Source | Innokin Official Website


The newly released Innokin Trine, an open system product from Innokin, complies with the upcoming new regulations in the European Union market.

Innokin Trine: A Revolutionary Rechargeable E-Cigarette with Replaceable Battery
Image source | Innokin official website


In addition, the main feature of Trine is its "three-in-one" structure: atomizer, detachable and rechargeable battery, control panel. At the same time, the detachable and rechargeable battery enhances the convenience and durability of the device.

Innokin Trine: A Revolutionary Rechargeable E-Cigarette with Replaceable Battery
Image source | Innokin brand official website


Specifically, the main product features of the Innokin Trine include:


E-liquid capacity: 2ml Nicotine concentration: Supports a variety of nicotine levels in e-liquid Battery capacity: 1000mAh removable battery Charging method: Supports Type-C fast charging.


Trine Power Hub charger charges


Backup batteries can also be purchased separately.


Power Mode: Provides a power output of 6-25W.


Function: - Suction activation


Support mouth to lung (MTL) or limit direct lung (RDL) inhale mode.


Compatible with a variety of e-liquid flavors.


Charging indicator light


The screen displays operational parameters such as output power and battery level.


Currently, the Innokin Trine has been listed on the official website of the Innokin e-cigarette brand and major distributor websites in Europe, with a selling price of approximately 19.95 euros.


In addition to the Innokin brand, other brands such as GOLISI and NEXIONE have also introduced similar products with replaceable batteries. 2Firsts will continue to monitor the latest products and market trends in replaceable battery e-cigarette products, providing the public with accurate and authoritative industry information.


We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

JTI Liggett Puts U.S. Value Cigarette Brands in Spotlight at 2026 NACS Show
JTI Liggett Puts U.S. Value Cigarette Brands in Spotlight at 2026 NACS Show
At the 2026 NACS Show in Las Vegas, JTI Liggett highlighted its value-priced cigarette portfolio, including LD and Montego, following JT Group's acquisition of Vector Group. The company's U.S. business reported market share gains, with LD sales volume rising 32.6% in the first half of 2026. Meanwhile, Ploom was displayed separately at Altria's booth under an existing partnership. JTI Liggett booth staff told 2Firsts that the company had not yet launched nicotine pouch products in the United States.
EXPO
Oct.09
NAS 2026 | FDA CTP Director Says PMTA Pathway Is “Predicated on Tobacco Harm Reduction”
NAS 2026 | FDA CTP Director Says PMTA Pathway Is “Predicated on Tobacco Harm Reduction”
At the 2026 New Approaches Summit in New York, FDA Center for Tobacco Products Director Bret Koplow said the PMTA pathway is “predicated on tobacco harm reduction.” He outlined four CTP priorities: youth prevention, helping adults quit or switch to lower-risk products, improving relative-risk communication, and reducing unauthorized products. Koplow also addressed flavored e-cigarettes, public risk perceptions, industry credibility and efforts to make PMTA reviews more efficient and predictable.
Sep.26
How Large Is France’s Off-Channel Tobacco Market? Logista Says It Has Become Structural, While the Official Estimate Is 17.7% and Some Industry Studies Put It Above 50%
How Large Is France’s Off-Channel Tobacco Market? Logista Says It Has Become Structural, While the Official Estimate Is 17.7% and Some Industry Studies Put It Above 50%
Logista France says tobacco consumption outside France’s official tobacconist network has become a large and structural market phenomenon, but official and industry estimates differ sharply. France’s TAFE study estimates that 17.7% of tobacco consumption escaped domestic taxation in 2023, with most of that volume attributed to cross-border purchasing rather than street sales. Some industry studies use broader off-channel definitions and put the figure above 50%. Meanwhile, French Customs seized 547.94 tonnes of tobacco in 2025, up 12%, showing continued pressure from illicit trade.
Sep.04
Product | FOGER Introduces Switch Pro 30K Nixodine Pod in U.S. Retail, Bringing 6-MN Related Formulation to High-Capacity Pod Platform
Product | FOGER Introduces Switch Pro 30K Nixodine Pod in U.S. Retail, Bringing 6-MN Related Formulation to High-Capacity Pod Platform
FOGER has introduced the Switch Pro 30K Nixodine Pod in U.S. retail channels, bringing a 6-methylnicotine (6-MN)-related formulation into its reusable Switch Pro 30K pod ecosystem. The product retains the existing reusable dock and magnetic replacement pod architecture, featuring a 19ml prefilled pod, dual-mesh heating and Normal/Boost modes. The Nixodine version is labeled nicotine-free in terms of conventional nicotine but uses a 5% Nixodine-related formulation. The product has appeared in U.S. retail and wholesale channels, with some listings indicating Kentucky-only availability.
Aug.28
U.S. Ninth Circuit Upholds FDA Denial of MH Global’s Flavored Vape PMTA Applications
U.S. Ninth Circuit Upholds FDA Denial of MH Global’s Flavored Vape PMTA Applications
The U.S. Court of Appeals for the Ninth Circuit upheld the FDA’s denial of MH Global LLC’s applications to market flavored electronic nicotine delivery systems (ENDS). The court ruled that FDA’s comparative-efficacy framework, which requires applicants to show that flavored products provide greater cessation or switching benefits than tobacco-flavored alternatives, is consistent with the Tobacco Control Act’s “appropriate for the protection of the public health” standard. The court also found that FDA was not required to establish the framework through notice-and-comment rulemaking.
Aug.26
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Eleftheria (Ria) Kioupritzi, a biopharmaceutical professional with more than 15 years of experience, has joined Philip Morris International as Director Scientific Affairs within Corporate Affairs. She previously served at Roche as Senior Scientific Communications Director for Neuroscience and Rare Diseases and worked extensively in spinal muscular atrophy. Her earlier career also covered competitive intelligence, clinical and regulatory monitoring, pipeline development and launch preparation. During her time working in Roche's SMA field, Evrysdi passed through several U.S. FDA milestones, including its initial approval, an expanded indication for younger infants and approval of a tablet formulation. Public records do not show that Kioupritzi herself led the FDA submissions.
Sep.22